---
title: Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405
nct_id: NCT02387554
overall_status: COMPLETED
phase: PHASE1
sponsor: Hanmi Pharmaceutical Company Limited
study_type: INTERVENTIONAL
primary_condition: Hypertension(HTN)
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02387554.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02387554"
ct_last_update_post_date: 2015-06-12
last_seen_at: "2026-05-12T06:20:58.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405

**Official Title:** A Randomized, Open-label, 4-way Crossover Single Dose Clinical Trial to Investigate the Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405 When Administered Alone and in Combination in Healthy Male Volunteers

**NCT ID:** [NCT02387554](https://clinicaltrials.gov/study/NCT02387554)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 33
- **Lead Sponsor:** Hanmi Pharmaceutical Company Limited
- **Collaborators:** Seoul National University Bundang Hospital
- **Conditions:** Hypertension(HTN)
- **Start Date:** 2014-08
- **Completion Date:** 2014-10
- **CT.gov Last Update:** 2015-06-12

## Brief Summary

The purpose of this study is to investigate the pharmacokinetic interaction and safety between HGP0904, HGP0608 and HGP1405 when administered alone and in combination in healthy male volunteers

## Eligibility

- **Minimum age:** 19 Years
- **Maximum age:** 45 Years
- **Sex:** MALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* 19\~45 years old
* Healthy men

Exclusion Criteria:

* Gastroentestinal disease affecting drug absorption
```

## Arms

- **HGP0904+HGP0608+HGP1405** (EXPERIMENTAL) — amlodipine + losartan + chlorthalidone
- **HGP0904** (ACTIVE_COMPARATOR) — amlodipine
- **HGP0608** (ACTIVE_COMPARATOR) — losartan
- **HGP1405** (ACTIVE_COMPARATOR) — chlorthalidone

## Interventions

- **HGP0904** (DRUG)
- **HGP0608** (DRUG)
- **HGP1405** (DRUG)

## Primary Outcomes

- **AUClast** _(time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr)_ — AUClast(Area under the curve to the last measurable concentration)
- **Cmax** _(time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr)_ — Cmax(maxium concentration)

## Secondary Outcomes

- **AUCinf** _(time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr)_
- **Tmax** _(time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr)_
- **T1/2** _(time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr)_
- **CL/F** _(time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr)_
- **Vz/F** _(time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr)_

## Locations (1)

- Seoul National University Bundang Hospital, Bundang, Gyeonggi-do, South Korea

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.seoul national university bundang hospital|bundang|gyeonggi-do|south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02387554.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02387554*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*